{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:22Z","timestamp":1792173442838,"version":"4.4.0"},"reference-count":64,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi231530-4\"><jats:title>Importance<\/jats:title><jats:p>Immune-related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non\u2013small cell lung cancer (NSCLC). However, studies have been small and the association between irAE severity and OS remains poorly defined.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231530-5\"><jats:title>Objective<\/jats:title><jats:p>To examine the association between irAEs and their severity with OS in patients with locally advanced or metastatic NSCLC receiving ICIs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231530-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective observational cohort study included patients with NSCLC receiving ICIs between March 1, 2014, and November 30, 2021, with follow-up until March 31, 2023. Data analysis was completed April 26, 2023. The Alberta Immunotherapy Database, a provincial, multicenter cohort, was used to capture data from patients receiving ICIs in Alberta, Canada. Participants included 803 patients 18 years or older who received at least 1 cycle of ICI (alone or with chemotherapy), agnostic to treatment line.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231530-7\"><jats:title>Exposure<\/jats:title><jats:p>Developing an irAE mandating delay or discontinuation of ICI therapy and\/or systematic corticosteroids for management of toxic effects (hereinafter referred to as clinically meaningful irAEs).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231530-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was association between irAEs and OS according to Kaplan-Meier analysis. Clinically meaningful irAEs were identified. Patients with poor prognosis (survival &amp;amp;lt;3 months) who may have died prior to irAE development were excluded from OS analysis, mitigating immortal time bias. Adjusted Cox proportional hazards regression analyses ascertained variables associated with OS.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231530-9\"><jats:title>Results<\/jats:title><jats:p>Among the 803 patients included in the analysis, the median age of patients with irAEs was 69.7 (IQR, 63.1-75.2) years and the median age of those without irAEs was 67.5 (IQR, 60.4-73.3) years, with comparable sex distribution (139 of 295 men [47.1%] and 156 of 295 women [52.9%] with irAEs vs 254 of 505 men [50.3%] and 251 of 505 women [49.7%] without irAEs). Mitigating immortal time bias (n\u2009=\u2009611), irAEs were associated with OS (median OS with irAEs, 23.7 [95% CI, 19.3-29.1] months; median OS without irAEs, 9.8 [95% CI, 8.7-11.4] months; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). No OS difference was associated with treatment in hospital vs as outpatients for an irAE (median OS, 20.8 [95% CI, 11.7-30.6] vs 25.6 [95% CI, 20.1-29.8] months; <jats:italic>P<\/jats:italic>\u2009=\u2009.33). Developing irAEs remained associated with OS in the total cohort after Cox proportional hazards regression with known prognostic characteristics (hazard ratio, 0.53 [95% CI, 0.40-0.70]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231530-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cohort study of 803 patients with locally advanced or metastatic NSCLC receiving ICIs, developing a clinically meaningful irAE was associated with improved OS. This association was not compromised by hospitalization for severe toxic effects. Whether and how ICI therapy resumption after an irAE is associated with OS warrants further study.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.52302","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:01:00Z","timestamp":1705593660000},"page":"e2352302","source":"Crossref","is-referenced-by-count":180,"title":["Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1001","volume":"7","author":[{"given":"Sarah","family":"Cook","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Samuel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Meyers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Stukalin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishjot","family":"Litt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randeep","family":"Sangha","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don G.","family":"Morris","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y. C.","family":"Heng","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah","family":"Pabani","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Dean","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Navani","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"3","key":"zoi231530r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"zoi231530r2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality.","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi231530r3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi231530r4","doi-asserted-by":"publisher","first-page":"LBA4","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4","article-title":"Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced\/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) =1%: open-label, phase 3 KEYNOTE-042 study.","volume":"36","author":"Lopes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"zoi231530r5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC.","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi231530r6","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1\u2013selected NSCLC.","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"10274","key":"zoi231530r7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non\u2013small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"zoi231530r8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi231530r9","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi231530r10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non\u2013small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi231530r11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407.","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"24","key":"zoi231530r12","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi231530r13","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer.","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi231530r14","doi-asserted-by":"publisher","first-page":"9000","DOI":"10.1200\/JCO.2021.39.15_suppl.9000","article-title":"First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non\u2013small cell lung cancer (NSCLC): two-year update from CheckMate 9LA.","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi231530r15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi231530r16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non\u2013small cell lung cancer treated with immune-checkpoint inhibitors.","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"zoi231530r17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/1120009X.2020.1849488","article-title":"Prognostic factors and effect on survival of immune-related adverse events in patients with non\u2013small-cell lung cancer treated with immune checkpoint blockage.","volume":"33","author":"Conde-Est\u00e9vez","year":"2021","journal-title":"J Chemother"},{"key":"zoi231530r18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/CMAR.S347852","article-title":"Predictive factors correlated with the development of immune-related adverse events in patients with non\u2013small cell lung cancer treated with immune checkpoint inhibitors.","volume":"14","author":"Sonehara","year":"2022","journal-title":"Cancer Manag Res"},{"key":"zoi231530r19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/LCTT.S254146","article-title":"Correlation of immune-related adverse events and effects of pembrolizumab monotherapy in patients with non\u2013small cell lung cancer.","volume":"11","author":"Noguchi","year":"2020","journal-title":"Lung Cancer (Auckl)"},{"key":"zoi231530r20","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3389\/fonc.2020.01677","article-title":"Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti\u2013PD-(L)1 blockade agents.","volume":"10","author":"Riudavets","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"zoi231530r21","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non\u2013small-cell lung cancer.","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"zoi231530r22","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non\u2013small cell lung cancer patients treated with nivolumab: a prospective cohort study.","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"4","key":"zoi231530r23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ijc.v150.4","article-title":"Risk factors for immune-related adverse events from anti\u2013PD-1 or anti\u2013PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.","volume":"150","author":"Huang","year":"2022","journal-title":"Int J Cancer"},{"issue":"11","key":"zoi231530r24","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non\u2013small-cell lung cancer treated with nivolumab.","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"issue":"7","key":"zoi231530r25","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00262-020-02536-5","article-title":"Outcomes associated with immune-related adverse events in metastatic non\u2013small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.","volume":"69","author":"Naqash","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"zoi231530r26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/10781552211067429","article-title":"Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness.","volume":"29","author":"Cortijo-Cascajares","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"zoi231530r27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cllc.2020.04.003","article-title":"A population-based study of immunotherapy-related toxicities in lung cancer.","volume":"21","author":"Cathcart-Rake","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"zoi231530r28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression =50% and their relationship with clinical outcomes.","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"zoi231530r29","first-page":"58","article-title":"Relationship between programmed cell death protein ligand 1 expression and immune-related adverse events in non\u2013small-cell lung cancer patients treated with pembrolizumab.","volume":"3","author":"Sugisaka","year":"2020","journal-title":"JMA J"},{"issue":"9","key":"zoi231530r30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non\u2013small cell lung cancer treated with PD-1 inhibitors.","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"zoi231530r31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non\u2013small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials.","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi231530r32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non\u2013small-cell lung cancer.","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"zoi231530r33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients.","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"zoi231530r34","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00262-021-03115-y","article-title":"The prognostic impact of mild and severe immune-related adverse events in non\u2013small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"zoi231530r35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630136","article-title":"Immune-related adverse events are associated with clinical benefit in patients with non\u2013small-cell lung cancer treated with immunotherapy plus chemotherapy: a retrospective study.","volume":"11","author":"Morimoto","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"zoi231530r36","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non\u2013small cell lung cancer.","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi231530r37","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1186\/s12885-022-10133-1","article-title":"Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non\u2013small cell lung cancer patients: a retrospective study.","volume":"22","author":"Kurokawa","year":"2022","journal-title":"BMC Cancer"},{"key":"zoi231530r38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non\u2013small cell lung cancer treated with nivolumab.","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"zoi231530r39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.607531","article-title":"Immune-related adverse events and their association with the effectiveness of PD-1\/PD-L1 inhibitors in non\u2013small cell lung cancer: a real-world study from China.","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"zoi231530r40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1064169","article-title":"Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.","volume":"13","author":"Sayer","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"zoi231530r41","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.bulcan.2020.04.019","article-title":"Occurrence and number of immune-related adverse events are independently associated with survival in advanced non\u2013small-cell lung cancer treated by nivolumab.","volume":"107","author":"Bouhlel","year":"2020","journal-title":"Bull Cancer"},{"issue":"5","key":"zoi231530r42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000511999","article-title":"The role of immune-related adverse events in prognosis and efficacy prediction for patients with non\u2013small cell lung cancer treated with immunotherapy: a retrospective clinical analysis.","volume":"99","author":"Sonehara","year":"2021","journal-title":"Oncology"},{"key":"zoi231530r43","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-003038","article-title":"Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.","author":"Valencia Soto","year":"2022","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"zoi231530r44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non\u2013small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"zoi231530r45","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.7150\/jca.49213","article-title":"Clinical characteristics correlate with outcomes of immunotherapy in advanced non\u2013small cell lung cancer.","volume":"11","author":"Huang","year":"2020","journal-title":"J Cancer"},{"issue":"1","key":"zoi231530r46","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.cllc.2018.09.005","article-title":"Efficacy of nivolumab and pembrolizumab in patients with advanced non\u2013small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis.","volume":"20","author":"Ksienski","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"zoi231530r47","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2147\/CMAR","article-title":"Proximal shift of colorectal cancer with increasing age in different ethnicities.","volume":"10","author":"Yang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"zoi231530r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2022.03.003","article-title":"Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors.","author":"Serino","year":"2022","journal-title":"Pulmonology"},{"key":"zoi231530r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014a systematic review and meta-analysis.","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"zoi231530r50","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer.","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi231530r51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2217\/imt-2022-0028","article-title":"Association of immune-related adverse events and efficacy in advanced non\u2013small-cell lung cancer: a systematic review and meta-analysis.","volume":"15","author":"Zhou","year":"2023","journal-title":"Immunotherapy"},{"issue":"16","key":"zoi231530r52","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.3390\/cancers14163878","article-title":"Grade 3-4 immune-related adverse events induced by immune checkpoint inhibitors in non\u2013small-cell lung cancer (NSCLC) patients are correlated with better outcome: a real-life observational study.","volume":"14","author":"Guezour","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"zoi231530r53","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/cancers11111713","article-title":"The Lung Immune Prognostic Index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors.","volume":"11","author":"Meyers","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"zoi231530r54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi231530r55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi231530r56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood-2008-09-177360","article-title":"Endogenous IL-17 contributes to reduced tumor growth and metastasis.","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"issue":"20","key":"zoi231530r57","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade.","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi231530r58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002512","article-title":"Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.","volume":"9","author":"G\u00e9rard","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"zoi231530r59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-021-04375-2","article-title":"Correlation between immune-related adverse events and the efficacy of PD-1\/PD-L1 inhibitors in the treatment of non\u2013small cell lung cancer: systematic review and meta-analysis.","volume":"89","author":"Zhang","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"zoi231530r60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1004663","article-title":"Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non\u2013small cell lung cancer.","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"zoi231530r61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703893","article-title":"Therapeutic and prognostic implications of immune-related adverse events in advanced non\u2013small-cell lung cancer.","volume":"11","author":"Daniello","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"zoi231530r62","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.21037\/tlcr","article-title":"Correlations between peripheral blood biomarkers and clinical outcomes in advanced non\u2013small cell lung cancer patients who received immunotherapy-based treatments.","volume":"10","author":"Shi","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"zoi231530r63","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627089","article-title":"Fatal adverse events associated with immune checkpoint inhibitors in non\u2013small cell lung cancer: a systematic review and meta-analysis.","volume":"8","author":"Yu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"zoi231530r64","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cllc.2022.07.015","article-title":"Immune checkpoint inhibitor rechallenge safety and efficacy in stage IV non\u2013small cell lung cancer patients after immune-related adverse events.","volume":"23","author":"Guo","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814052\/cook_2024_oi_231530_1704835806.04872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:01:03Z","timestamp":1705593663000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52302","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}